首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Polythiol-Containing, Recombinant Mannosylated-Albumin Is a Superior CD68(+)/CD206(+) Kupffer Cell-Targeted Nanoantioxidant for Treatment of Two Acute Hepatitis Models
【24h】

Polythiol-Containing, Recombinant Mannosylated-Albumin Is a Superior CD68(+)/CD206(+) Kupffer Cell-Targeted Nanoantioxidant for Treatment of Two Acute Hepatitis Models

机译:含多硫醇的重组甘露糖基化白蛋白是一种出色的CD68(+)/ CD206(+)Kupffer细胞靶向纳米抗氧化剂,可用于治疗两种急性肝炎模型

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Since reactive oxygen species (ROS) derived from Kupffer cells (KC), especially CD68(+) KC, play a key role in the induction of hepatic oxidative stress and injuries, we developed a polythiolated- and mannosylated human serum albumin (SH-Man-HSA), which functions as a novel nanoantioxidant for delivering thiol to CD68(+) KC. In vitro electron paramagnetic resonance coupled with pharmacokinetics and immunohistochemical studies showed that SH-Man-HSA possessed powerful radical-scavenging activity and rapidly and selectively delivered thiols to the liver via mannose receptor (CD206) on CD68(+) cells. SH-Man-HSA significantly improved the survival rate of concanavalin-A (Con-A)-treated mice. Moreover, SH-Man-HSA exhibited excellent hepatoprotective functions, not by decreasing tumor necrosis factor or interferon-gamma production that is closely associated with Con-A-induced hepatitis, but by suppressing ROS production. Interestingly, the protective effect of SH-Man-HSA was superior to N-acetyl cysteine (NAC). This could be attributed to the difference in the inhibition of hepatic oxidative stress between the two antioxidants depending on their potential for thiol delivery to the liver. Similar results were also observed for acetaminophen (APAP)-induced hepatopathy models. Flow cytometric data further confirmed that an increase in F4/80(+)/ROS+ cells was dramatically decreased by SH-Man-HSA. The administration of SH-Man-HSA at 4 hours following a Con-A or APAP injection also exhibited a profound hepatoprotective action against these hepatitis models, whereas this was not observed for NAC. It can be concluded therefore that SH-Man-HSA has great potential for use in a rescue therapy for hepatopathy as a nanoantioxidant because of its ability to efficiently and rapidly deliver thiols to CD68(+)/CD206(+) KC.
机译:由于源自库普弗细胞(KC)的活性氧(ROS)(尤其是CD68(+)KC)在诱导肝氧化应激和损伤中起关键作用,因此我们开发了多硫醇化和甘露糖基化的人血清白蛋白(SH-Man -HSA),它作为一种新型的纳米抗氧化剂,可将硫醇传递至CD68(+)KC。体外电子顺磁共振结合药代动力学和免疫组化研究表明,SH-Man-HSA具有强大的自由基清除活性,并通过CD68(+)细胞上的甘露糖受体(CD206)将硫醇快速选择性地递送至肝脏。 SH-Man-HSA显着提高了伴刀豆球蛋白A(Con-A)治疗的小鼠的存活率。此外,SH-Man-HSA表现出优异的肝保护功能,不是通过降低与Con-A诱导的肝炎密切相关的肿瘤坏死因子或干扰素-γ产生,而是通过抑制ROS产生。有趣的是,SH-Man-HSA的保护作用优于N-乙酰半胱氨酸(NAC)。这可以归因于两种抗氧化剂之间对肝氧化应激的抑制作用的差异,这取决于它们将硫醇递送到肝脏的潜力。对乙酰氨基酚(APAP)诱导的肝病模型也观察到了相似的结果。流式细胞仪数据进一步证实,SH-Man-HSA显着降低了F4 / 80(+)/ ROS +细胞的增加。 Con-A或APAP注射后4小时给予SH-Man-HSA也对这些肝炎模型表现出了深刻的肝保护作用,而NAC并未观察到。因此可以得出结论,SH-Man-HSA具有作为纳米抗氧化剂用于肝病抢救治疗的巨大潜力,因为它能够有效且快速地将硫醇传递到CD68(+)/ CD206(+)KC中。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号